Smartphone app boosts self-care for bladder cancer patients with urostomy
NCT ID NCT07201441
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a health cloud platform accessed via smartphone to help patients who have a urostomy after bladder cancer surgery. The platform allowed patients to check their medical info and communicate with nurses. Researchers measured whether this improved patients' ability to care for their stoma and reduced anxiety. The study involved 42 adults aged 18 to 80 who had undergone bladder removal and urostomy surgery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- health cloud platform with mobile app for patient education and communication
- What this could lead to
- If successful, this approach could help urostomy patients feel more confident in managing their stoma care at home and reduce anxiety.
- What could go wrong
- This is a small, completed study with only 42 participants, so results may not apply to all patients. The intervention relies on smartphone use, which may not be accessible to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
42 people
The number who actually took part.
- Started
-
Jan 2023
- Finished
-
Sep 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Those with clear consciousness, distinct self - expression and without mental abnormalities. Individuals whose age is between 18 and 80 years old (inclusive), and whose self - care ability (Barthel Index) score is greater than 90 points. Those who are clearly aware of the diagnosis and have undergone total cystectomy with urostomy. Patients without depression. Patients or their family members are able to use WeChat. Voluntarily participate in this study and sign the informed consent form. Exclusion Criteria: * Patients with tumor metastasis or combined with other tumors. Those with visual impairment. Vulnerable groups, including patients with mental illnesses, those with cognitive impairment, critically ill patients, minors, pregnant women, illiterate people, etc.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Urinary bladder neoplasms are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310016, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A pill instead of surgery? trial tests vepugratinib against Low-Grade bladder cancer
- Can a bladder rinse before surgery keep bladder cancer at bay?
- Mapping bladder cancer care: a nationwide look at Real-World treatment
- Can AI outthink cancer experts? a landmark trial pits five AIs against tumor boards
- Bladder cancer surgery: what happens after the bladder is removed?
- Bladder cancer drug delivered directly: a new hope for BCG failures